20.08.2017

ESC-Jahreskongress 2017 – die perkutane Koronarintervention im Fokus

Unter dem Leitthema „40 Jahre PCI“ steht die perkutane Koronarintervention (PCI) im Fokus des diesjährigen Kongresses der European Society of Cardiology (ESC). Die Konferenz findet vom 26. bis 30. August 2017 in Barcelona statt. Die aktuellen leitlinienbasierten Empfehlungen zur antithrombotischen Therapie nach PCI haben wir hier für Sie zusammengefasst.

Mit dem Finger gemaltes Herz mit Herzfrequenz

© vege / Fotolia

Spotlight-Thema des ESC-Kongresses 2017: 40 Jahre perkutane Koronarintervention

INFORMATION FÜR FACHKRÄFTE

[DocCheckStop]
Quellen:

  1. Kolh P et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014; 46: 517-592. https://www.ncbi.nlm.nih.gov/pubmed/25173601
  2. Bennett J et al. Percutaneous coronary intervention, a historical perspective looking to the future. Journal of Thoracic Disease 2013; 5: 367-370. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698257/
  3. Stefanini GG et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISARTEST 3, ISARTEST 4, and LEADERS randomized trials. European Heart Journal 2012; 33: 1214-1222. http://dx.doi.org/10.1093/eurheartj/ehs086
  4. Byrne RA et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf 2009; 32: 749-770. https://www.ncbi.nlm.nih.gov/pubmed/19670915
  5. Webseite des ESC-Kongress 2017; verfügbar unter https://www.escardio.org/Congresses-%26-Events/ESC-Congress; abgerufen am 31.07.2017.
  6. T. Bonzel et al. Leitlinie – Perkutane Koronarintervention (PCI). Clin Res Cardiol 2008; 97: 513 – 547. http://leitlinien.dgk.org/files/2008_Leitlinie_Perkutane_Koronarinterventionen_PCI.pdf
  7. Levine GN et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: e574-651. www.scai.org/asset.axd?id=213d9d76-357e-4104-8753-ec7f7eb672e2
  8. Fachinformation Plavix®. Sanofi-Aventis Deutschland GmbH, Frankfurt. Stand 2017. https://mein.sanofi.de/produkte/Plavix/Downloads?id=2caf054a-ae52-4a1b-9cfa-c41470b26be1
  9. Fachinformation Kengrexal®. Chiesi Pharmaceuticals GmbH, Hamburg. http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/003773/WC500188098.pdf
  10. Fachinformation EFIENT®,  Daiichi-Sankyo GmbH, München und Lilly Deutschland GmbH, Bad Homburg. Stand der Information: Mai 2015. http://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/RI_rhb/2013/FI-Efient.pdf?__blob=publicationFile&v=2
  11. Fachinformation Brillique™. AstraZeneca, Wedel bei Hamburg. Stand 2011. https://farmde.com/files/Beipackzettel-brilique-90-mg-filmtabletten-56-st-07560021-bp.pdf
  12. Wiviott SD et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 2007; 357: 2001-2015. http://www.nejm.org/doi/full/10.1056/NEJMoa0706482
  13. Wallentin L et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 2009; 361: 1045-1057. http://www.nejm.org/doi/full/10.1056/NEJMoa0904327
  14. Montalescot G et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731. https://www.ncbi.nlm.nih.gov/pubmed/19249633
  15. Udell JA et al. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITONTIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv 2014; 7: 604-612. https://www.ncbi.nlm.nih.gov/pubmed/24947719
  16. Wiviott SD et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636. https://www.ncbi.nlm.nih.gov/pubmed/18757948

Fazit

Prasugrel (Efient®) ist für ein breites Spektrum von ACS-Patienten die sich einer PCIunterziehen eine wichtige Therapieoption.

Möchten Sie mehr zum Thema „antithrombotische Therapie“ erfahren? Stimmen Sie ab:

Quellen:

  1. Kolh P et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014; 46: 517-592. https://www.ncbi.nlm.nih.gov/pubmed/25173601
  2. Bennett J et al. Percutaneous coronary intervention, a historical perspective looking to the future. Journal of Thoracic Disease 2013; 5: 367-370. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698257/
  3. Stefanini GG et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISARTEST 3, ISARTEST 4, and LEADERS randomized trials. European Heart Journal 2012; 33: 1214-1222. http://dx.doi.org/10.1093/eurheartj/ehs086
  4. Byrne RA et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf 2009; 32: 749-770. https://www.ncbi.nlm.nih.gov/pubmed/19670915
  5. Webseite des ESC-Kongress 2017; verfügbar unter https://www.escardio.org/Congresses-%26-Events/ESC-Congress; abgerufen am 31.07.2017.
  6. T. Bonzel et al. Leitlinie – Perkutane Koronarintervention (PCI). Clin Res Cardiol 2008; 97: 513 – 547. http://leitlinien.dgk.org/files/2008_Leitlinie_Perkutane_Koronarinterventionen_PCI.pdf
  7. Levine GN et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: e574-651. www.scai.org/asset.axd?id=213d9d76-357e-4104-8753-ec7f7eb672e2
  8. Fachinformation Plavix®. Sanofi-Aventis Deutschland GmbH, Frankfurt. Stand 2017. https://mein.sanofi.de/produkte/Plavix/Downloads?id=2caf054a-ae52-4a1b-9cfa-c41470b26be1
  9. Fachinformation Kengrexal®. Chiesi Pharmaceuticals GmbH, Hamburg. http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/003773/WC500188098.pdf
  10. Fachinformation EFIENT®,  Daiichi-Sankyo GmbH, München und Lilly Deutschland GmbH, Bad Homburg. Stand der Information: Mai 2015. http://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/RI_rhb/2013/FI-Efient.pdf?__blob=publicationFile&v=2
  11. Fachinformation Brillique™. AstraZeneca, Wedel bei Hamburg. Stand 2011. https://farmde.com/files/Beipackzettel-brilique-90-mg-filmtabletten-56-st-07560021-bp.pdf
  12. Wiviott SD et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 2007; 357: 2001-2015. http://www.nejm.org/doi/full/10.1056/NEJMoa0706482
  13. Wallentin L et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 2009; 361: 1045-1057. http://www.nejm.org/doi/full/10.1056/NEJMoa0904327
  14. Montalescot G et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731. https://www.ncbi.nlm.nih.gov/pubmed/19249633
  15. Udell JA et al. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITONTIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv 2014; 7: 604-612. https://www.ncbi.nlm.nih.gov/pubmed/24947719
  16. Wiviott SD et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636. https://www.ncbi.nlm.nih.gov/pubmed/18757948